InMed Pharmaceuticals Clinical Trial Program Moving Forward In 2023

In this new Trade To Black Podcast, Shadd Dales speaks again with InMed Pharmaceuticals (Nasdaq: INM) CEO Eric Adams to talk about the company core pharmaceutical pipeline. Currently, the two most prominent candidates include Phase 2a clinical trial compound INM-755 for the treatment of Epidermolysis bullosa (EB) and INM-088, which is in preclinical studies as a potential treatment for glaucoma.

Regarding InMed Pharmaceutical’s EB clinical trial, which is characterized as its most advanced, the company is currently in the enrollment phase to determine the safety and efficacy of INM-755, a cannabinol (CBN)-based skin cream. Mr. Adams reports that the trial in moving forward despite the challenge in recruitment, extending the enrollment period so that the company can get “the full cohort of our targeted 20 patients.” within the next couple of months. A full data readout is expected early in the second half of 2023.

EB is a rare disease that causes fragile, blistering skin. The blisters may appear in response to minor injury, even from heat, rubbing or scratching. In severe cases, the blisters may occur inside the body, such as the lining of the mouth or stomach. Compounding the problem, the afflicted are prone to infections from open sores that never seem to heal properly. Currently, there is no universally effective treatment for the disease.

Mr. Adams also updates investors on INM-088 for the potential treatment of glaucoma. Currently, the compound is still in the pre-clinical stage of development, however, clinical program development is underway. InMed Pharmaceuticals has already completed a pre-Investigational New Drug (pIND) application meeting with the FDA and gained alignment on the proposed design of the Phase 1-2 clinical trial program, anticipated to commence in 1H 2024.

Interestingly, cannabinol demonstrates “neuro-protective activity” to the neurons at the back of the eye. As such, cannabinol (or like formulations such as INM-088) may prevent these cells from dying due to the increased intraocular (IOP) pressure caused by glaucoma.

Indeed, a 2021 study titled “Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma” concluded that CBN promotes neuroprotection, abrogates changes in ECM protein, and normalizes the IOP levels in the eye—thereby validating the therapeutic potential for CBN in the treatment of glaucoma.

Click on the embedded link to see more of our newest interview with InMed Pharmaceuticals CEO Eric Adams, in his own words.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More